CeriBell, Inc. (CBLL)
Nasdaq: CBLL · Electromedical & Electrotherapeutic Apparatus · Sunnyvale, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Feb 24, 2026 | Feb 25, 2025 | · |
| Revenue | 89,063 | 65,444 | 45,225 |
| Cost of revenue | 10,789 | 8,694 | 7,062 |
| Gross profit | 78,274 | 56,750 | 38,163 |
| Research and development | 19,143 | 13,562 | 8,995 |
| Sales and marketing | 73,082 | 49,055 | 38,922 |
| General and administrative | 44,451 | 33,842 | 20,287 |
| Total operating expenses | 136,676 | 96,459 | 68,204 |
| Operating income | -58,402 | -39,709 | -30,041 |
| Interest expense | 1,890 | 1,992 | 2,098 |
| Other income (expense), net | 6,880 | 2,742 | 2,638 |
| Income before income taxes | -53,412 | -40,455 | -29,453 |
| Income tax expense | 0 | 0 | 11 |
| Net income including non-controlling interests | -53,412 | -40,455 | -29,464 |
| Net income | -53,412 | -40,455 | -29,464 |
| Earnings per share, basic | -1.46 | -3.39 | -5.56 |
| Earnings per share, diluted | -1.46 | -3.39 | -5.56 |
| Weighted average shares, basic | 36,542,048 | 11,949,973 | 5,303,715 |
| Weighted average shares, diluted | 36,542,048 | 11,949,973 | 5,303,715 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding